April 21, 2014

The 2013-2014 cough-cold season has been characterized as a moderate season with $7.5 billion in sales across total U.S. multi-outlet channels for the 52 weeks ended Jan. 26, according to IRI.

March 24, 2014

Genentech announced that the Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, or CIU, which is a form of chronic hives.

February 18, 2014

A study by researchers at the University of Nebraska Medical Center found that vitamin D as an add-on therapy could provide some relief for chronic hives, a condition with no cure and few treatment options.

January 27, 2014

The Food and Drug Administration will hold a public meeting of the Allergenic Products Advisory Committee on Tuesday to determine the safety and efficacy of Ragwitek, a short ragweed pollen allergen extract tablet for sublingual use.

November 8, 2013

A study being presented this week at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology found hay fever is more prevalent in children living in the southeastern and southern states, ACAAI announced Friday.

October 21, 2013

Nearly 1-in-50 people in the United States are at risk of severe allergic reactions, according to a new study announced Monday by the Asthma and Allergy Foundation of America.

August 20, 2013

A majority of respondents to a survey commissioned by drug maker Sanofi say that they or their children experienced a severe allergic reaction while traveling.

August 12, 2013

Perrigo Co. announced that it has received final approval from the Food and Drug Administration for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS Body Oil.

May 21, 2013

A subsidiary of drug maker Mylan is sponsoring a campaign to draw attention to severe allergic reactions.

January 29, 2013

Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.